ChimeriVax

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2014
01220002014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
To address concerns that a flavivirus vaccine/wild-type recombinant virus might have a high mosquito infectivity phenotype, the… (More)
Is this relevant?
2008
2008
Candidate vaccine ChimeriVax viruses are attenuated, efficacious, safe, and highly unlikely to be transmitted by arthropod… (More)
Is this relevant?
Review
2007
Review
2007
Acambis (formerly Peptide Therapeutics) is developing ChimeriVax-West Nile, a recombinant live-attenuated vaccine which… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
A randomized double-blind Phase I Trial was conducted to evaluate safety, tolerability, and immunogenicity of a yellow fever (YF… (More)
Is this relevant?
2005
2005
Current requirements for control of live viral vaccines, including yellow fever 17D, produced from potentially neurotropic wild… (More)
Is this relevant?
2004
2004
The vector competence of mosquitoes for chimeric viruses being developed as vaccines to protect against dengue (DEN) virus… (More)
Is this relevant?
2003
2003
In 1999 West Nile (WN) virus was introduced to North America where this flavivirus has spread rapidly among wildlife (especially… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
ChimeriVax is a live, attenuated recombinant virus constructed from yellow fever (YF) 17D in which the envelope protein genes of… (More)
Is this relevant?
2002
2002
Chimeric yellow fever (YF)-dengue (DEN) viruses (ChimeriVax-DEN) were reconstructed to correct amino acid substitutions within… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A chimeric yellow fever (YF)-dengue type 2 (dengue-2) virus (ChimeriVax-D2) was constructed using a recombinant cDNA infectious… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?